ArticleCardiovascular diagnosis and therapy2026
Quantitative assessment and clinical value of right-to-left shunt in patent foramen ovale using three-dimensional transesophageal echocardiography combined with right-heart contrast: a prospective study.
Article in Cardiovascular diagnosis and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: A patent foramen ovale (PFO) is a common congenital cardiac condition characterized by a persistent communication between the right and left atria, which can facilitate a right-to-left shunt (RLS). This study aimed to determine the diagnostic accuracy, reproducibility, and prognostic value of PFO shunt volume quantified by three-dimensional transesophageal echocardiography (3D-TEE) combined with right-heart contrast echocardiography. Methods: In this prospective study, 100 patients with suspected PFO were prospectively enrolled and allocated in a 7:3 ratio to a training cohort (n=70) and a validation cohort (n=30). Each participant underwent two-dimensional transthoracic echocardiography (2D-TTE), two-dimensional transesophageal echocardiography (2D-TEE), and 3D-TEE. The total shunt volume (V_total) was calculated using voxel-based grey-scale integration. The optimal cut-off value was determined in the training set with the Youden index and then applied to the validation set. A multi-modality "hard reference" standard served as the diagnostic gold standard for method comparison. Reproducibility was evaluated with intraclass correlation coefficients (ICCs). All patients were followed for 36 months; stroke or transient ischemic attack (TIA) risk was analyzed with Kaplan-Meier curves and Firth-penalized Cox models, and changes in migraine frequency and residual shunt volume were recorded. Results: Eight baseline 3D structural indices, including tunnel length, slit width, leaflet excursion and shunt volume, showed no significant difference between cohorts (P>0.05). V_total, V_peak and t_dur demonstrated excellent repeatability (ICC =0.91-0.94; coefficient of variation 6.96-8.27%). The optimal threshold of 22.93 µL yielded an area under the curve (AUC) of 0.92 in the training set and 0.89 in the validation set (DeLong, P=0.27), with a sensitivity of 92%, specificity of 89%, and a diagnostic odds ratio (DOR) of 89.78, outperforming 2D-TTE and 2D-TEE. Kaplan-Meier analysis showed a 3-year stroke/TIA-free survival of 79% for shunt volume ≥22.93 µL versus 96% below the threshold (12 events, log-rank P=0.01); V_total ≥23 µL remained an independent predictor [hazard ratio (HR) =5.27, P=0.04]. Migraine frequency fell significantly over follow-up (P=0.001), and residual shunt volume at six months was lower after closure than with medical therapy (P<0.001). Conclusions: 3D-TEE with right-heart contrast precisely quantifies PFO shunt volume; a threshold of 22.93 µL is reproducible and predicts both diagnostic status and long-term outcomes, supporting its use in stroke risk stratification, closure decision-making and therapeutic monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.